This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Subscribe To Our Newsletter & Stay Updated
